De Novo device
ReneuRx (Neural Ice)
Brixton Biosciences · Injectable For Thermal Treatment Of Musculoskeletal Pain (SJA, Class II) · First FDA decision Aug 21, 2026, newest Aug 21, 2026Chronic painKnee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
1
Naming "ReneuRx"
MAUDE reports
0
Brand "ReneuRx", since 2015
PubMed studies
0
Mentioning "ReneuRx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ReneuRx (Neural Ice)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ReneuRx (Neural Ice)New device typeDe Novo
DEN250067 · Decided Aug 21, 2026 · 249 days after receipt
Device type: Injectable For Thermal Treatment Of Musculoskeletal Pain (SJA) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "ReneuRx", any status and sponsor, newest update first.
- ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip PainPivotal-lookingRecruiting
Brixton Biosciences, Inc.Not on our public-company list
NCT07568015 · 100 participants (planned) · Start Jul 27, 2026 · Primary completion Nov 1, 2027
Device: ReneuRx · For: Greater Trochanteric Pain Syndrome; Greater Trochanteric Pain Syndrome of Both Lower Limbs; Lateral Hip Pain
Sites: Sun City, Arizona; Johns Creek, Georgia; New Orleans, Louisiana · 11 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ReneuRx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SJA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ReneuRx"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.